SEPNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Septerna, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$36.38+0.03 (+0.08%)
Close on Oct 19, 2026
- Market cap
- $1.64B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
47M of 47M shares
Institutional holders
154
48 new, 16 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 27 sales
Net sold $76.06M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Trv Gp V, LLC | 6,215,591 | 14.00% | 13G (passive) amendment | Mar 31, 2025 |
| Peter Kolchinsky | 5,525,324 | 11.80% | 13D (active) amendment | Aug 12, 2026 |
| Driehaus Capital Management LLC | 4,433,058 | 9.83% | 13G (passive) amendment | Jun 30, 2026 |
| Lampert Mark N | 4,396,124 | 9.90% | 13G (passive) amendment | Mar 31, 2025 |
| Samsara BioCapital, L.P. | 2,768,520 | 6.20% | 13G (passive) | Oct 28, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SEPN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 6,995,858 | 14.99% | $234.29M | – | 2.04% |
| Trv Gp V, LLC | 6,215,591 | 13.32% | $208.16M | – | 41.78% |
| Driehaus Capital Management LLC | 4,433,058 | 9.50% | $148.46M | +37,486 | 0.86% |
| Trv Gp Vi, LLC | 4,211,659 | 9.02% | $141.05M | – | 60.72% |
| Samsara BioCapital, LLC | 3,149,128 | 6.75% | $105.46M | – | 8.66% |
| Goldman Sachs Group Inc | 3,062,766 | 6.56% | $102.57M | +156,339 | 0.01% |
| BlackRock, Inc. | 1,932,088 | 4.14% | $64.71M | +109,914 | 0.00% |
| Siren, L.L.C. | 1,900,000 | 4.07% | $63.63M | −100,000 | 1.29% |
| Avoro Capital Advisors LLC | 1,337,500 | 2.87% | $44.79M | – | 0.40% |
| Jupiter Topco LLC | 1,307,500 | 2.80% | $43.72M | New | 0.02% |
| Vanguard Capital Management LLC | 1,221,673 | 2.62% | $40.91M | +24,711 | 0.00% |
| Primecap Management Co/Ca/ | 1,167,382 | 2.50% | $39.10M | +118,548 | 0.02% |
| First Light Asset Management, LLC | 963,260 | 2.06% | $32.26M | +230,400 | 1.96% |
| ADAR1 Capital Management, LLC | 940,747 | 2.02% | $31.51M | −149,071 | 1.44% |
| Geode Capital Management, LLC | 679,163 | 1.46% | $22.75M | +34,017 | 0.00% |
| State Street Corp | 652,630 | 1.40% | $21.86M | +21,183 | 0.00% |
| Loomis Sayles & Co L P | 624,752 | 1.34% | $20.92M | New | 0.03% |
| Casdin Capital, LLC | 553,268 | 1.19% | $18.53M | – | 0.93% |
| Catalio Capital Management, LP | 536,152 | 1.15% | $17.96M | +241,792 | 3.37% |
| Algert Global LLC | 397,487 | 0.85% | $13.31M | +376,452 | 0.16% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 154 | 47M | 100.0% | 48 / 49 | 32 / 16 | 5M | 3M |
| Q1 2026 | 124 | 46M | 98.4% | 28 / 44 | 30 / 24 | 5M | 3M |
| Q4 2025 | 122 | 46M | 97.7% | 45 / 31 | 27 / 5 | 5M | 4M |
| Q3 2025 | 82 | 45M | 95.5% | 10 / 32 | 16 / 16 | 2M | 2M |
| Q2 2025 | 89 | 44M | 95.2% | 25 / 31 | 19 / 6 | 4M | 5M |
| Q1 2025 | 71 | 45M | 97.0% | 20 / 25 | 12 / 19 | 8M | 7M |
| Q4 2024 | 71 | 44M | 94.5% | 71 / 0 | 0 / 0 | 44M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SEPN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 927,665 | 1.99% | $31.07M | 0.00% | Jun 30, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 824,582 | 1.77% | $28.41M | 0.38% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 578,523 | 1.24% | $19.37M | 0.02% | Jun 30, 2026 |
| Driehaus Small Cap Growth Fund | 417,859 | 0.90% | $13.99M | 0.87% | Jun 30, 2026 |
| Loomis Sayles Small Cap Growth Fund | 338,579 | 0.73% | $11.34M | 0.50% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 261,547 | 0.56% | $8.76M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 242,456 | 0.52% | $8.35M | 0.02% | Jul 31, 2026 |
| iShares Biotechnology ETF | 192,645 | 0.41% | $6.45M | 0.07% | Jun 30, 2026 |
| Driehaus Micro Cap Growth Fund | 158,272 | 0.34% | $5.30M | 0.89% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 138,834 | 0.30% | $4.65M | 0.03% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 126,696 | 0.27% | $4.24M | 0.99% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 116,900 | 0.25% | $3.53M | 0.01% | May 31, 2026 |
| Column Small Cap Select Fund | 110,886 | 0.24% | $3.35M | 0.18% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 109,770 | 0.24% | $3.32M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 108,128 | 0.23% | $3.27M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jeffrey Finer | Chief Executive Officer, Director | 826,907 | 1.77% | Feb 10, 2026 |
| Rajiv Patni | Chief Medical Officer | – | – | Sep 10, 2026 |
| Daniel D. Long | SVP, Drug Discovery | 96,412 | 0.21% | Sep 3, 2026 |
| Elizabeth Bhatt | President and COO | 199,209 | 0.43% | Aug 13, 2026 |
| Samira Shaikhly | Chief People Officer | 793 | 0.00% | Jun 30, 2026 |
| Gil M. Labrucherie | Chief Financial Officer | 40,000 | 0.09% | Feb 10, 2026 |
| Jae B. Kim | Chief Medical Officer | – | – | Feb 10, 2026 |
| Uwe Klein | SVP, Biological Sciences | 119,912 | 0.26% | Feb 10, 2026 |
| Mark Andrew Wilson | Chief Legal Officer | – | – | Feb 10, 2026 |
| Ran Xiao | Interim CFO | 58,069 | 0.12% | Oct 24, 2024 |
| Capital Healthcare Fund LP RA | Director, 10% owner | – | – | Aug 14, 2026 |
| Rajeev M. Shah | Director, 10% owner | 725,443 | 1.55% | Aug 14, 2026 |
| RA Capital Nexus Fund III, L.P. | Director | – | – | Aug 14, 2026 |
| Peter Kolchinsky | Director, 10% owner | – | – | Aug 14, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | – | – | Aug 14, 2026 |
| Shalini Sharp | Director | – | – | Jun 30, 2026 |
| Alan Ezekowitz | Director | 117,420 | 0.25% | Jun 30, 2026 |
| Keith Michael Gottesdiener | Director | – | – | Jun 30, 2026 |
| Bernard Coulie | Director | – | – | Jun 30, 2026 |
| Jeffrey K. Tong | Director | – | – | Jun 30, 2026 |
| Abraham Bassan | Director | – | – | Jun 30, 2026 |
| Jake Simson | Director | – | – | Jun 30, 2026 |
| Third Rock Ventures GP VI, L.P. | 10% owner | 10,280,191 | 22.02% | Aug 14, 2026 |
| Third Rock Ventures VI, L.P. | 10% owner | – | – | Aug 14, 2026 |
| Trv Gp Vi, Llc | 10% owner | – | – | Aug 14, 2026 |
| Trv Gp V, Llc | 10% owner | 12,241,003 | 26.22% | Aug 14, 2026 |
| Third Rock Ventures GP V, LP | 10% owner | 10,427,250 | 22.34% | Aug 14, 2026 |
| Third Rock Ventures V, L.P. | 10% owner | – | – | Aug 14, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Daniel D. Long SVP, Drug Discovery | Sep 1, 2026 | Sale(10b5-1 plan) | −3,333 | $37.83 | $126.09K | 96,412 |
| Daniel D. Long SVP, Drug Discovery | Sep 1, 2026 | Option exercise | +3,333 | $2.76 | $9.20K | 99,745 |
| Rajeev M. Shah Director, 10% owner | Aug 12, 2026 | Sale | −746,500 | $42.50 | $31.73M | 725,443 |
| Rajeev M. Shah Director, 10% owner | Aug 12, 2026 | Sale | −746,500 | $42.50 | $31.73M | 4,777,415 |
| Third Rock Ventures GP VI, L.P. 10% owner | Aug 12, 2026 | Sale(10b5-1 plan) | +147,059 | $50.27 | $7.39M | 6,068,532 |
| Third Rock Ventures GP VI, L.P. 10% owner | Aug 12, 2026 | Sale(10b5-1 plan) | +141 | $51.08 | $7.20K | 6,068,391 |
| Elizabeth Bhatt President and COO | Aug 11, 2026 | Option exercise | +6,319 | $2.76 | $17.44K | 199,209 |
| Elizabeth Bhatt President and COO | Aug 11, 2026 | Sale(10b5-1 plan) | −25,000 | $44.00 | $1.10M | 174,209 |
| Elizabeth Bhatt President and COO | Aug 11, 2026 | Option exercise | +18,681 | $6.81 | $127.22K | 192,890 |
| Daniel D. Long SVP, Drug Discovery | Aug 3, 2026 | Option exercise | +1,518 | $2.76 | $4.19K | 99,746 |
| Daniel D. Long SVP, Drug Discovery | Aug 3, 2026 | Option exercise | +1,816 | $2.76 | $5.01K | 98,228 |
| Daniel D. Long SVP, Drug Discovery | Aug 3, 2026 | Sale(10b5-1 plan) | −1,000 | $33.98 | $33.98K | 98,746 |
| Daniel D. Long SVP, Drug Discovery | Aug 3, 2026 | Sale(10b5-1 plan) | −2,334 | $34.68 | $80.94K | 96,412 |
| Elizabeth Bhatt President and COO | Jul 15, 2026 | Option exercise | +4,000 | $6.81 | $27.24K | 178,209 |
| Elizabeth Bhatt President and COO | Jul 15, 2026 | Sale(10b5-1 plan) | −4,000 | $33.99 | $135.96K | 174,209 |
| Daniel D. Long SVP, Drug Discovery | Jul 1, 2026 | Sale(10b5-1 plan) | −2,100 | $34.10 | $71.61K | 97,645 |
| Daniel D. Long SVP, Drug Discovery | Jul 1, 2026 | Option exercise | +3,333 | $2.76 | $9.20K | 99,745 |
| Daniel D. Long SVP, Drug Discovery | Jul 1, 2026 | Sale(10b5-1 plan) | −1,233 | $34.81 | $42.92K | 96,412 |
| Samira Shaikhly Chief People Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −2,178 | $35.18 | $76.62K | 793 |
| Samira Shaikhly Chief People Officer | Jun 29, 2026 | Option exercise | +2,178 | $6.81 | $14.83K | 2,971 |
| Daniel D. Long SVP, Drug Discovery | Jun 22, 2026 | Option exercise | +4,471 | $11.70 | $52.31K | 111,412 |
| Daniel D. Long SVP, Drug Discovery | Jun 22, 2026 | Sale(10b5-1 plan) | −8,000 | $35.10 | $280.80K | 103,412 |
| Daniel D. Long SVP, Drug Discovery | Jun 22, 2026 | Sale(10b5-1 plan) | −7,000 | $35.97 | $251.79K | 96,412 |
| Daniel D. Long SVP, Drug Discovery | Jun 22, 2026 | Option exercise | +10,529 | $2.76 | $29.06K | 106,941 |
| Samira Shaikhly Chief People Officer | Jun 12, 2026 | Sale(10b5-1 plan) | −6,250 | $35.08 | $219.25K | 793 |
| Samira Shaikhly Chief People Officer | Jun 12, 2026 | Option exercise | +6,250 | $11.70 | $73.13K | 7,043 |
| Samira Shaikhly Chief People Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −1,346 | $28.79 | $38.75K | 3,682 |
| Samira Shaikhly Chief People Officer | Jun 1, 2026 | Option exercise | +4,355 | $1.55 | $6.75K | 5,148 |
| Samira Shaikhly Chief People Officer | Jun 1, 2026 | Option exercise | +943 | $2.76 | $2.60K | 6,091 |
| Samira Shaikhly Chief People Officer | Jun 1, 2026 | Option exercise | +637 | $2.76 | $1.76K | 6,728 |
| Samira Shaikhly Chief People Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −2,889 | $29.66 | $85.69K | 793 |
| Samira Shaikhly Chief People Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −1,700 | $27.78 | $47.23K | 5,028 |
| Samira Shaikhly Chief People Officer | May 26, 2026 | Option exercise | +11,798 | $6.81 | $80.34K | 12,591 |
| Samira Shaikhly Chief People Officer | May 26, 2026 | Sale(10b5-1 plan) | −11,798 | $30.06 | $354.65K | 793 |
| Elizabeth Bhatt President and COO | Apr 15, 2026 | Sale(10b5-1 plan) | −1,101 | $25.24 | $27.79K | 174,535 |
| Elizabeth Bhatt President and COO | Apr 15, 2026 | Option exercise | +4,000 | $6.81 | $27.24K | 178,209 |
| Elizabeth Bhatt President and COO | Apr 15, 2026 | Sale(10b5-1 plan) | −326 | $25.86 | $8.43K | 174,209 |
| Elizabeth Bhatt President and COO | Apr 15, 2026 | Sale(10b5-1 plan) | −2,573 | $23.76 | $61.13K | 175,636 |
| Samira Shaikhly Chief People Officer | Mar 2, 2026 | Option exercise | +53,714 | $1.55 | $83.26K | 54,507 |
| Samira Shaikhly Chief People Officer | Mar 2, 2026 | Option exercise | +11,638 | $2.76 | $32.12K | 66,145 |
| Samira Shaikhly Chief People Officer | Mar 2, 2026 | Option exercise | +5,101 | $2.76 | $14.08K | 71,246 |
| Samira Shaikhly Chief People Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −4,090 | $27.51 | $112.52K | 67,156 |
| Samira Shaikhly Chief People Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −66,363 | $28.14 | $1.87M | 793 |
| Elizabeth Bhatt President and COO | Feb 18, 2026 | Option exercise | +4,000 | $6.81 | $27.24K | 178,209 |
| Elizabeth Bhatt President and COO | Feb 18, 2026 | Sale(10b5-1 plan) | −2,200 | $28.46 | $62.61K | 176,009 |
| Elizabeth Bhatt President and COO | Feb 18, 2026 | Sale(10b5-1 plan) | −1,800 | $29.58 | $53.24K | 174,209 |
| Daniel D. Long SVP, Drug Discovery | Nov 10, 2025 | Sale | −3,501 | $18.06 | $63.23K | 92,911 |
| Uwe Klein SVP, Biological Sciences | Aug 18, 2025 | Option exercise | +4,935 | $2.76 | $13.62K | 15,387 |
| Uwe Klein SVP, Biological Sciences | Aug 18, 2025 | Option exercise | +7,621 | $6.81 | $51.90K | 23,008 |
| Uwe Klein SVP, Biological Sciences | Aug 18, 2025 | Option exercise | +10,452 | $2.76 | $28.85K | 10,452 |
| Jeffrey Finer CEO and President, Director | Apr 3, 2025 | Option exercise | +5,000 | $2.76 | $13.80K | 826,907 |
| Jeffrey Finer CEO and President, Director | Apr 2, 2025 | Option exercise | +50,000 | $2.76 | $138.00K | 821,907 |
| Alan Ezekowitz Director | Mar 7, 2025 | Buy | +13,319 | $6.93 | $92.30K | 117,420 |
| Alan Ezekowitz Director | Mar 6, 2025 | Buy | +41,355 | $6.00 | $248.13K | 104,101 |
| Alan Ezekowitz Director | Mar 5, 2025 | Buy | +37,835 | $5.82 | $220.20K | 62,746 |
| Alan Ezekowitz Director | Mar 4, 2025 | Buy | +7,491 | $6.35 | $47.57K | 24,911 |
| Jeffrey Finer CEO and President, Director | Feb 27, 2025 | Buy | +3,000 | $5.80 | $17.40K | 771,907 |
| Gil M. Labrucherie Chief Financial Officer | Feb 27, 2025 | Buy | +3,718 | $5.85 | $21.75K | 40,000 |
| Jeffrey Finer CEO and President, Director | Feb 26, 2025 | Buy | +4,000 | $5.70 | $22.80K | 768,907 |
| Jeffrey Finer CEO and President, Director | Feb 25, 2025 | Buy | +10,000 | $5.68 | $56.80K | 764,907 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Long Daniel Officer | Oct 1, 2026 | 10,001 | $391.34K | Oct 1, 2026 | Exercise of Stock Options |
| Shaikhly Samira Officer | Oct 1, 2026 | 12,592 | $492.72K | Oct 1, 2026 | Exercise of Stock Options |
| RA Capital Nexus Fund III, L.P. Affiliate | Aug 12, 2026 | 746,500 | $35.97M | Aug 12, 2026 | IPO / Private round |
| Capital Healthcare Fund LP RA affiliate | Aug 12, 2026 | 746,500 | $35.97M | Aug 12, 2026 | IPO |
| Third Rock Ventures V, L.P. 10% Stockholder | Aug 12, 2026 | 147,200 | $7.51M | Aug 12, 2026 | Original Issuance |
| P. Bhatt Elizabeth Officer | Aug 11, 2026 | 29,000 | $1.13M | Aug 11, 2026 | Exercise of Stock Options |
| P. Bhatt Elizabeth Officer | Jul 15, 2026 | 4,000 | $138.16K | Jul 15, 2026 | Exercise of Stock Options |
| Kim Jae Officer | Jun 26, 2026 | 2,438 | $89.24K | Jun 26, 2026 | Employee Stock Purchase Plan |
| Kim Jae Officer | Jun 22, 2026 | 94,339 | $3.33M | Jun 22, 2026 | Stock Option Exercise |
| Long Daniel Officer | Jun 22, 2026 | 25,000 | $904.25K | Jun 22, 2026 | Exercise of Stock Options |
| Shaikhly Samira Officer | Jun 12, 2026 | 8,428 | $286.80K | Jun 12, 2026 | Exercise of Stock Options |
| Shaikhly Samira Officer | May 26, 2026 | 11,798 | $334.59K | May 26, 2026 | Exercise of Stock Options |
| Shaikhly Samira Officer | Mar 2, 2026 | 76,388 | $2.22M | Mar 2, 2026 | Exercise of Stock Options |
| Bhatt Elizabeth Officer | Feb 18, 2026 | 8,000 | $242.40K | Feb 18, 2026 | Exercise of Stock Options |
| David Long Daniel Officer | Nov 10, 2025 | 3,501 | $63.22K | Nov 10, 2025 | Employee Stock Purchase Plan |